[1] |
Wang C, Xu J, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study. Lancet, 2018, 391(10131):1706-1717. doi: 10.1016/S0140-6736(18)30841-9.
doi: 10.1016/S0140-6736(18)30841-9
URL
|
[2] |
Zhou M, Wang H, Zeng X, et al.Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systema-tic analysis for the Global Burden of Disease Study 2017.Lancet, 2019,394(10204): 1145-1158. doi: 10.1016/S0140-6736(19)30427-1.
doi: 10.1016/S0140-6736(19)30427-1
|
[3] |
Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacer-bation in chronic obstructive pulmonary disease. N Engl J Med, 2010, 363(12): 1128-1138. doi: 10.1056/NEJMoa0909883.
doi: 10.1056/NEJMoa0909883
URL
|
[4] |
Han MK, Quibrera PM, Carretta EE, et al. Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort. Lancet Respir Med, 2017, 5(8):619-626. doi: 10.1016/S2213-2600(17)30207-2.
doi: 10.1016/S2213-2600(17)30207-2
URL
|
[5] |
Mishlanov VJ, Shubin IV, Bekker KN, et al. Chronic obstructive pulmonary disease patients electronic register analysis: the effectiveness of patient’s dynamic follow up and evaluation of treatment program. Ter Arch, 2019, 91(1):78-83. doi: 10.26442/00403660.2019.01.000034.
doi: 10.26442/00403660.2019.01.000034
|
[6] |
Müllerova H, Chigbo C, Hagan GW,et al. The natural history of community-acquired pneumonia in COPD patients: a population database analysis. Respir Med, 2012, 106(8):1124-1133. doi: 10.1016/j.rmed.2012.04.008.
doi: 10.1016/j.rmed.2012.04.008
pmid: 22621820
|
[7] |
Liu DS, Han XD, Liu XD. Current Status of Community-Acquired Pneumonia in Patients with Chronic Obstructive Pulmonary Disease. Chin Med J (Engl), 2018, 131(9):1086-1091. doi: 10.4103/0366-6999.230727.
doi: 10.4103/0366-6999.230727
|
[8] |
Liapikou A, Polverino E, Ewig S, et al. Severity and outcomes of hospitalized community-acquired pneumonia in COPD patients. Eur Respir, 2012, 39(4):855-861. doi: 10.1183/09031936.00067111.
doi: 10.1183/09031936.00067111
URL
|
[9] |
Gómez-Junyent J, Garcia-Vidal C, Viasus D,et al. Clinical features, etiology and outcomes of community-acquired pneumonia in patients with chronic obstructive pulmonary disease. PLoS One, 2014, 9(8):e105854. doi: 10.1371/journal.pone.0105854.
doi: 10.1371/journal.pone.0105854
URL
|
[10] |
Søgaard M, Madsen M, Løkke A, et al. Incidence and outcomes of patients hospitalized with COPD exacerbation with and without pneumonia. Int J Chron Obstruct Pulmon Dis, 2016, 11:455-465. doi: 10.2147/COPD.S96179.
doi: 10.2147/COPD.S96179
|
[11] |
Yamauchi Y, Yasunaga H, Matsui H, et al. Comparison of clinical characteristics and outcomes between aspiration pneumonia and community-acquired pneumonia in patients with chronic obstructive pulmonary disease. BMC Pulm Med, 2015, 15:69. doi: 10.1186/s12890-015-0064-5.
doi: 10.1186/s12890-015-0064-5
URL
|
[12] |
Shin B, Kim SH, Yong SJ, et al. Early readmission and mortality in acute exacerbation of chronic obstructive pulmonary disease with community-acquired pneumonia. Chron Respir Dis, 2019, 16:1479972318809480. doi: 10.1177/1479972318809480.
doi: 10.1177/1479972318809480
|
[13] |
Ma Y, Huang K, Liang C, et al. Real-world antibiotic use in treating acute exacerbations of chronic obstructive pulmonary disease (AECOPD) in China: Evidence from the ACURE study. Front Pharmacol, 2021, 12:649884. doi: 10.3389/fphar.2021.649884.
doi: 10.3389/fphar.2021.649884
URL
|
[14] |
中华医学会呼吸病学分会慢性阻塞性肺疾病学组, 中国医师协会呼吸医师分会慢性阻塞性肺疾病工作委员会. 慢性阻塞性肺疾病诊治指南(2021年修订版).中华结核和呼吸杂志, 2021, 44(3):170-205. doi: 10.3760/cma.j.cn112147-20210109-00031.
doi: 10.3760/cma.j.cn112147-20210109-00031
|
[15] |
张丽, 范忠杰, 周凡.慢性阻塞性肺疾病急性加重期肺部感染患者的病原菌分布、耐药性及危险因素分析. 中国病原生物学杂志, 2019, 14(12):1456-1459. doi: 10.13350/j.cjpb.191219.
doi: 10.13350/j.cjpb.191219
|
[16] |
于子情. 住院慢性阻塞性肺疾病急性加重患者主要细菌分布变迁及耐药特性趋势. 北京: 协和医学院, 2019. doi: 10.27648/d.cnki.gzxhu.2019.000567.
doi: 10.27648/d.cnki.gzxhu.2019.000567
|
[17] |
Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (updated 2016) [EB/OL].(2016-01-01) [2016-04-05].https://goldcopd.org/wp-content/uploads/2016/02/wms-GOLD-2016-FINAL.pdf
|
[18] |
Rubinsztajn R, Przybyłowski T, Maskey-Warzęchowska M, et al. Analiza składu ciała mierzonego metodᶏ bioimpendancjiu chorych na przewlekłᶏ obturacyjnę chorobę płuc [Body composition analysis performed by bioimpedance in patients with chronic obstructive pulmonary disease]. Pol Merkur Lekarski, 2016, 41(244):180-183.
|
[19] |
Catalfo G, Crea L, Lo Castro T, et al. Depression, body mass index, and chronic obstructive pulmonary disease-a holistic approach. Int J Chron Obstruct Pulmon Dis, 2016, 11:239-249. doi: 10.2147/COPD.S84347.
doi: 10.2147/COPD.S84347
|
[20] |
冉丕鑫, 王辰, 姚婉贞,等. 体重指数与慢性阻塞性肺疾病及生活质量的关系. 中华结核和呼吸杂志, 2007, 30(1):18-22. doi: 10.3760/j:issn:1001-0939.2007.01.005.
doi: 10.3760/j:issn:1001-0939.2007.01.005
|
[21] |
Hsu MF, Ho SC, Kuo HP, et al. Mini-nutritional assessment (MNA) isuseful for assessing the nutritional status of patients with chronic obstructive pulmonary disease: a cross-sectional study. COPD, 2014, 11(3):325-332. doi: 10.3109/15412555.2013.863274.
doi: 10.3109/15412555.2013.863274
pmid: 24475999
|
[22] |
Ramos FM, Rossato LT, Ramires BR, et al. Comparison of predictive equations of resting energy expenditure in older adults with chronic obstructive pulmonary disease. Rev Port Pneumol (2006), 2017, 23(1):40-42. doi: 10.1016/j.rppnen.2016.08.005.
doi: 10.1016/j.rppnen.2016.08.005
|
[23] |
Yamamoto Y, Yoshikawa M, Tomoda K, et al. Distribution of bone mineral content is associated with body weight and exercise capacity in patients with chronic obstructive pulmonary disease. Respiration, 2014, 87(2):158-164. doi: 10.1159/000355095.
doi: 10.1159/000355095
URL
|
[24] |
Liu Y, Pleasants RA,Croft JB,et al. Body mass index, respiratory conditions, asthma, and chronic obstructive pulmonary disease. Respir Med, 2015, 109(7):851-859. doi: 10.1016/j.rmed.2015.05.006.
doi: 10.1016/j.rmed.2015.05.006
|
[25] |
聂晓红, 熊曙光, 王晓虹,等.体质指数对慢性阻塞性肺疾病急性加重期患者治疗反应性及气道黏液高分泌的影响. 中国急救医学, 2019, 39(4):332-337. doi: 10.3969/j.issn.1002-1949.2019.04.008.
doi: 10.3969/j.issn.1002-1949.2019.04.008
|
[26] |
钟贞, 邓碉, 张婷. 慢性气道炎症黏液高分泌的治疗药物研究进展. 重庆医学, 2014, 43(13):1644-1646.
|
[27] |
Chang C, Zhu H, Shen N, et al. Bacterial infection, airway and systemic inflammation and clinical outcomes before and after treatment of AECOPD, a longitudinal and cross-sectional study. COPD, 2015, 12(1):19-30. doi: 10.3109/15412555.2014.898043.
doi: 10.3109/15412555.2014.898043
pmid: 24800883
|
[28] |
Barnes PJ. Inflammatory endotypes in COPD. Allergy, 2019, 74(7):1249-1256. doi: 10.1111/all.13760.
doi: 10.1111/all.13760
pmid: 30834543
|
[29] |
Choi J, Oh JY, Lee YS, et al. The association between blood eosinophilpercent and bacterial infection in acute exacerbation of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis, 2019, 14:953-959. doi: 10.2147/COPD.S197361.
doi: 10.2147/COPD.S197361
URL
|
[30] |
Kolsum U, Donaldson GC, Singh R, et al. Blood and sputum eosinophils in COPD; relationship with bacterial load. Respir Res, 2017, 18(1):88. doi: 10.1186/s12931-017-0570-5.
doi: 10.1186/s12931-017-0570-5
URL
|
[31] |
Southworth T, Higham A, Kolsum U, et al. The relationship between airway immunoglobul in activity and eosinophils in COPD. J CellMol Med, 2021, 25(4):2203-2212. doi: 10.1111/jcmm.16206.
doi: 10.1111/jcmm.16206
|
[32] |
Legrand F, Tomasevic N, Simakova O, et al. The eosinophil surface receptor epidermal growth factor-like module containing mucin-like hormone receptor 1 (EMR1): a novel therapeutic target for eosinophilic disorders. J Allergy ClinImmunol, 2014, 133(5):1439-1447.e14478. doi: 10.1016/j.jaci.2013.11.041.
doi: 10.1016/j.jaci.2013.11.041
URL
|
[33] |
Kvarnhammar AM, Cardell LO. Pattern-recognition receptors in human eosinophils. Immunology, 2012, 136(1):11-20. doi: 10.1111/j.1365-2567.2012.03556.x.
doi: 10.1111/j.1365-2567.2012.03556.x
pmid: 22242941
|